1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D
DANNE T, PETTUS J, GIACCARI A, CARIOU B, RODBARD H, WEINZIMER S, BONNEMAIRE M, SAWHNEY S, WANG S, CASTRO R, GARG S. 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D. Diabetes 2019, 68 DOI: 10.2337/db19-1220-p.Peer-Reviewed Original ResearchOptimized insulin therapyInsulin therapySpouse/partnerSanofi USDiabetes careDohme Corp.Novo Nordisk A/SSanofi-AventisEli LillyMerck SharpAdvisory PanelPhase 3 studyLexicon PharmaceuticalsOptimal glycemic controlRisk of hypoglycemiaLevel 2 hypoglycemiaLower ratesAmgen Inc.Boehringer Ingelheim PharmaceuticalsDual SGLT1Important hypoglycemiaMannKind CorporationPatient yearsWeek 52Glycemic control816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D)
COMMISSARIAT P, ROETHKE L, VOLKENING L, BUTLER D, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D). Diabetes 2019, 68 DOI: 10.2337/db19-816-p.Peer-Reviewed Original ResearchDiabetes careBurden of T1DSelf-care burdenDiabetes technologyType 1 diabetesEli LillyArtificial pancreasUnderwent thematic analysisT1D durationNovo Nordisk A/SCarbohydrate countingSpouse/partnerCare burdenSemi-structured qualitative interviewsT1D careJanssen PharmaceuticalsMedtronic MiniMedPatients' hopeAP uptakeHeart rate monitorT1DDiabetesYoung adultsSpeakers bureauCare817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) Survey
COMMISSARIAT P, VOLKENING L, ROETHKE L, GUO Z, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) Survey. Diabetes 2019, 68 DOI: 10.2337/db19-817-p.Peer-Reviewed Original ResearchDiabetes careYoung personLess diabetes distressType 1 diabetesEli LillyInternal consistencyAdvanced diabetes technologiesMale sexDiabetes distressNovo Nordisk A/SSpouse/partnerGood internal consistencyT1D careDiabetesJanssen PharmaceuticalsMedtronic MiniMedMultidisciplinary teamTreatment surveySignificant associationPsychosocial outcomesYouth ages 8T1DCeiling effectsTotal scoreIllness identity